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Abstract 
Importance: The patient’s perspective on chemotherapy-related side effects is becoming 
increasingly acknowledged both in experimental clinical trials and in the clinical practice. 
Objective: To evaluate how breast cancer patients receiving standard adjuvant 
chemotherapy report and grade side effects using a ten-item, paper questionnaire derived 
from the US National Cancer Institute’s (NCIs) Common Terminology Criteria for Adverse 
Events (CTCAE) v4.0 and to compare patient with doctor reports.  
Design, setting and participants: The questionnaire was administered to 604 patients at 
11 sites after the first and third cycle of adjuvant chemotherapy between January 2011 and 
October 2013. CTCAE v4.0 definitions of grade of severity for nausea, vomiting, 
constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were 
translated into Italian and rephrased. Side effect information was also extracted from the 
medical charts to compare to patient-reported data.  
Main outcomes and measures: Differences in side effects reporting between paired 
questionnaires were studied by the McNemar Test and the Wilcoxon signed rank test. 
Agreement between patient and doctor side effect reporting (grade 0 vs. grade ≥1) was 
studied using Cohen’s kappa statistic. The effect of the number of patients enrolled at each 
Institution on the magnitude of discrepancy in side effect reporting between patients and 
doctors was studied by linear regression. 
Results: 596 and 581 questionnaires were collected after cycles 1 and 3, respectively. A 
median of 82% of fields were filled in. A corresponding doctor questionnaire completed from 
chart data was available for 594 and 573 patient questionnaires. The frequency and severity 
of chemotherapy-related side effects were consistently greater in patient-reported than 
doctor-reported data. As a result, inter-rater agreement was low for most side effects, 
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ranging from 0.10 for anorexia to 0.51 for vomiting (Cohen’s kappa statistic). There was a 
strong and significant positive correlation between the magnitude of the discrepancy in the 
frequency of reporting side effects and the number of patients enrolled at each site. 
Conclusions and relevance: Adherence to reporting adjuvant chemotherapy-related side 
effects using the CTCAE system is high in women undergoing adjuvant chemotherapy for 
breast cancer. Workload may contribute to agreement discrepancies by limiting the doctor-
patient relationship.    
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Introduction 
 Accurate reporting of treatment-related side effects is crucial for the appropriate 
management of cancer patients. In routine clinical practice, side effect reporting is pivotal in 
the decision-making process for dose modifications (e.g., dose reduction, treatment delay 
or withdrawal), supportive care administration, and prophylaxis. Side effect reporting 
(occurrence and grade of severity) is mandatory and highly standardized in clinical trials of 
new drugs or that compare newer treatments or regimens with an established gold standard 
1-3. The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) is the most widely used protocol for the description and grading of treatment-
related side effects in cancer therapy trials 4. CTCAE items include laboratory abnormalities, 
objective clinical findings, and subjective side effects experienced by the patient during 
and/or after drug exposure. The collection, coding, and grading of patient-reported adverse 
events is usually based on information abstracted from the patient’s medical records, making 
the use of a standardized system like the CTCAE demanding and resource-intensive for the 
clinical research team. Furthermore, the patient experience may not be fully captured by the 
physicians or nurses documenting clinical findings. Several papers from clinical trials have 
highlighted discrepancies in the side effects reported by medical staff and patients, with 
doctors frequently underestimating the incidence and severity of side effects 5-11. Since 
underreporting of chemotherapy-related side effects is a problem even in the highly 
controlled clinical trial environment, it is likely to be even more pronounced in routine clinical 
practice, where reporting does not follow strict standards. Consequently, there is growing 
interest in including “patient-reported outcomes” (PROs) in a CTCAE-compliant manner, 
where PROs are subjective reports from patients without medical interpretation (e.g., quality 
of life questionnaires) 12-17.  
 Because the use of a standard reporting system like CTCAE in routine clinical 
practice is attractive, yet challenging to implement 18, we established a prospective study in 
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mid-2010 to evaluate how breast cancer patients receiving standard adjuvant chemotherapy 
report and grade side effects using a ten-item, paper questionnaire (hereinafter referred to 
as “questionnaire”). The questionnaire was derived from the CTCAE v4.0 definitions and 
converted to Italian. The side effects reported by patients were also compared to those 
described by the treating oncologists who were informed of, but not formally involved in, the 
study. To minimize bias from cancer-associated symptoms, women with non-metastatic 
breast cancer undergoing standard adjuvant chemotherapy after breast surgery were 
studied.  
Patients and Methods 
Eligibility criteria 
 Women aged 18 years or over who had undergone surgery for operable breast 
cancer and were candidates for first-time adjuvant chemotherapy outside a clinical trial were 
eligible for study. Patients were asked to fill in the questionnaire twice: first at the end of the 
first chemotherapy cycle (usually on the day scheduled for the second cycle of 
chemotherapy) and the second at the end of the third cycle (usually on day scheduled for 
the fourth cycle of chemotherapy). Patients completed the questionnaires in the waiting 
room. Since it has previously been shown that the timing of questionnaire completion with 
respect to seeing the oncologist does not introduce significant bias 5, patients were able to 
complete the questionnaires before or after visiting the treating oncologist but before 
administration of chemotherapy. Oncology staff provided no assistance with filling in the 
questionnaires, but a dedicated nurse at each center provided a detailed explanation of the 
questionnaire at the time of informed consent before the first cycle of chemotherapy. 
Furthermore, patients were provided with a diary to use at home, to facilitate documenting 
the onset and duration (in days) of side effects in relation to receiving chemotherapy. 
However, home diaries were not collected as part of the study material. Treating oncologists 
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were provided with study details (i.e., the items listed in the questionnaire) but were not 
formally involved in the design and execution of the study and were not notified of patients’ 
participation in the study. The protocol was approved by the Ethical Committees of the 
participating Institutions. Each patient was required to sign an informed consent before 
entering the study. 
Patient questionnaire  
 A ten-item paper questionnaire was developed in which the side effect definitions and 
severity grades were translated into Italian from CTCAE v4.0. The 10 items were: nausea, 
vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain (generic), paresthesia, 
and dyspnea. These items were selected from a longer list due to their incidence in this 
group of patients, their considerable subjective component, and because they usually 
partially or completely resolve at the time of the next cycle of chemotherapy. Consequently, 
their reporting is unlikely to be consistent unless the patients are specifically asked.  
 The presence, grade, and duration of each item was recorded, with duration 
subdivided into day of onset, duration in days, and persistence at the time of questionnaire 
administration; i.e, five fields in total. A sample of the Italian questionnaire and its English 
translation are available in the on-line only supplemental material (eFigure 1 Appendix 1, 
respectively). Patients were asked to indicate if, after the previous chemotherapy 
administration, the side effect occurred. If the response was “yes” then patients indicated 
which of a set of statements best described their worst experience of that specific side effect, 
where each statement corresponded to the grades of severity described in CTCAE v4.0. For 
example, grade 2 nausea corresponded to “I felt nauseated and, because of that, I ate and 
drank less than usual”. Finally, patients were asked to report the day of onset of each side 
effect with respect to the timing of previous chemotherapy (e.g., day 3; third day after 
chemotherapy administration), the duration of side effect in days (any severity), and/or 
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whether the side effect persisted at the time of completing the questionnaire.  When the 
Italian translation of CTCAE v4.0 became available and was endorsed by the Italian 
Association of Medical Oncology in mid 2011 (available at: 
http://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/position+paper/CTCAE+
in+the+pocket/1%2C1004%2C1%2C), the questionnaire was re-checked and no 
corrections were needed due to translational discrepancies.  
Doctor questionnaire 
 The dedicated nurse at each center extracted side effect information from the medical 
records of enrolled patients after the first and third adjuvant chemotherapy cycle to complete 
“doctor” questionnaires. These questionnaires were managed exclusively by nurses and 
were not available to the treating doctors. Furthermore, the nurses managing doctor 
questionnaires were different to those collecting patient questionnaires at each center. 
Statistical methods 
 Percentages and absolute frequencies of symptom grades were calculated for all 
symptoms reported in patient and doctor questionnaires. For each symptom, differences in 
incidence (grade 0 vs grade ≥1) and severity (mean grade) between the first and second set 
of questionnaires were assessed using McNemar’s test and the Wilcoxon signed rank test, 
respectively. Agreement between patient and doctor side effect reporting (grade 0 vs. grade 
≥1) was studied on a “per-patient” basis using Cohen’s kappa statistic 19. Both weighted and 
not weighted Cohen’s K statistics were also computed to assess agreement on each grade 
(grade 0 vs grade 1 vs grade 2 vs grade 3 vs grade 4).   The proportion of pairs for which 
patients and doctors assigned identical grades was computed, along with the proportion of 
pairs that disagreed by one point for each symptom and the proportion that disagreed by 
two or more points.  Finally, for each symptom the relationship between the number of 
patients enrolled at each site and the discrepancy in reporting, defined as  percentage of 
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doctor questionnaires where grade was different from that reported by patient, was 
evaluated using ordinary least square regression. Statistical significance was set at p<0.05. 
Results 
Patient questionnaires after cycles 1 and 3 
 A total of 604 women (median age 53.4 years, interquartile range (I.Q.R.) 45.0-62.7) 
were enrolled between January 2011 and October 2013 at 11 Italian sites. The number of 
patients enrolled at each site varied between 6 and 236 (eTable 1, on-line only). Three 
patients withdrew consent prior to starting the first cycle of adjuvant chemotherapy. The 
relevant demographics of the remaining 601 patients are reported in eTable 2 (on-line only). 
A total of 596 and 581 patient questionnaires were collected after cycles 1 and 3 of adjuvant 
chemotherapy, respectively. Of these, 594 and 573 had a corresponding questionnaire 
extracted from the medical charts at the same time point. The median percentage of 
completed fields was 82% (I.Q.R. 80-88%) for both patient questionnaires. The percentage 
of fields not filled in for each questionnaire item (i.e., left blank) is shown in eTable3 (online 
only): the percentage of incomplete fields was very low and did not exceed 6.28% for four 
of the five fields. However, due to the high percentage of incomplete data on persistence or 
resolution of symptoms at the time of the visit , variables related to symptom duration were 
not analyzed here. 
 The results of the two patient questionnaires are summarized in Table 1 
(crosstabulated raw data are shown in eTable 4, online only). There was a reduction in 
vomiting (severity), diarrhea (both incidence and severity), and pain (both incidence and 
severity), and a statistically significant increase in dysgeusia (both incidence and severity) 
and dyspnea (both incidence and severity)  in the second patient-completed questionnaire. 
With respect to doctors’ questionnaires (crossutabulated raw data are shown in eTable 5, 
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online only), only an increase in the incidence (2% vs 4%, p = 0.01) and severity (mean 
grade 0.3 vs 0.7, p = 0.03) of dyspnea was recorded.  
Comparisons between patient and doctor questionnaires 
 Comparisons between patient and doctor questionnaires after the first chemotherapy 
cycle are summarized in Table 2 (crosstabulated raw data are shown in eTable 6, online 
only). The reporting incidence (any grade) was higher in patients than doctors for all side 
effect items, as was severity (figure 1). Focusing on incidence, patients reported 
constipation, anorexia, and dysgeusia almost twice as frequently as doctors and fatigue 
three times more frequently than doctors. Notably, paresthesia and dyspnea were rarely 
reported by doctors but were reported by 23% and 25% of patients, reaching grade 2 or 
higher in 4% and 10% of patients, respectively. A similar pattern was observed in data 
collected after the third cycle of chemotherapy (data not shown). Agreement in toxicity 
reporting (grade 0 vs. grade ≥1) between patients and doctors for each item after the first 
chemotherapy cycle is summarized in Table 4. For most items except vomiting, agreement 
was below the definition of “acceptable” (Cohen’s kappa statistic <0.40) 20, which was 
mirrored in the second set of questionnaires (not shown). This low level of agreement could 
mostly be explained by underreporting by doctors (Table 4).  Assessing overall agreement 
on toxicity grade by both weighted and non-weighted Cohen’s K statistics and using multiple 
imputation to account for missing data provided similar results (eTable 7, online only). 
Since the number of patients enrolled at each site varied widely (Table 1s, online only), we 
sought to assess whether the discrepancies observed between patients and physicians 
when assessing toxicity (each item, any grade) were associated with the number of patients 
enrolled. A strong and significant positive association was demonstrated for all ten items 
included in the questionnaire (Figure 2). Similar results were also observed for the second 
questionnaire (data not shown).  
10 
 
 
Discussion 
 The first aim of this study was to assess whether women undergoing adjuvant 
chemotherapy for operable breast cancer are able to report and grade ten common 
subjective side effects using a CTCAE v4.0-derived questionnaire. Secondly, due to the 
widely recognized problem of underestimating the incidence and severity of chemotherapy-
related side effects by doctors, patient-derived information was compared to that extracted 
from their medical charts.   
 There was a very high questionnaire response rate (98% and 95% returned a 
completed questionnaire at each time point), a high proportion of filled-in fields (82% for both 
the first and second questionnaire), and a low percentage of blank fields with the exception 
of the question regarding persistence or resolution of toxicity at the time of chemotherapy 
visit. For this reason, we decided not to analyze the duration of side effects here. However, 
we are currently analyzing the patient diaries in detail to resolve this issue.  
 There were significant discrepancies in the reported occurrence and severity of each 
of the ten items between patients and doctors. Consequently, there was also low agreement 
in incidence (grade 0 vs. grade ≥1) and grading, mainly due to underreporting by doctors. 
Several other authors have reported a similar phenomenon 5-11. For example, Di Maio and 
colleagues recently studied patients enrolled in three prospective clinical trials: one studying 
elderly patients with breast cancer receiving adjuvant chemotherapy and two studying 
patients with advanced non-small cell lung carcinoma receiving first-line treatment 9. The 
authors compared patient and doctor reporting of six chemotherapy-related side effects 
(anorexia, nausea, vomiting, constipation, diarrhea, and hair loss) after each of the initial 
three cycles of chemotherapy. Doctors used CTCAE v2.0, while patients completed PRO 
questionnaires issued by the European Organization for Research and Treatment of Cancer 
(EORTC) that included chemotherapy-related side effects rated on a severity scale of “not 
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at all”,  “ a little”,  “quite a bit”, and “very much”. Agreement between doctors and patients 
was poor, mainly due to doctors underestimating both the incidence and severity of side 
effects. Notably, kappa values for patient and doctor agreement for the five side effects 
common to our study (anorexia, nausea, vomiting, constipation and diarrhea) were 
remarkably similar to those reported here. These findings suggest that poor doctor and 
patient agreement in side effect reporting is consistent between diverse patient groups 
(cancer free or metastatic disease), type of treatment received, and management setting 
(prospective clinical trial or standard treatment).  
 Our findings also hint at possible reasons for this reproducible phenomenon. First, 
pairwise comparisons between the two patient questionnaires showed trends toward 
reduced vomiting, diarrhea, and pain. This suggests that doctors may have correctly 
identified the side effects and delivered appropriate management, but because vomiting and 
diarrhea are common, doctors may not have deemed them sufficiently important to report in 
the charts. Second, there was a statistically significant correlation between discrepancies in 
side effect reporting and the number of patients enrolled at each institution. Data that we 
collected during the pre-study surveys provide a possible explanation for this finding 
(eTable1, online only). With two exceptions, the number of patient accrued corresponded to 
enrolment commitment, which had to be estimated on the basis of expected number of 
patients eligible for the study and allocated resources of over a 2-year period. Therefore, we 
speculate that patient volume and the resources assigned to patient management might be 
determinants of the discrepancy between doctor and patient reporting of side effects. In 
particular, when time is constrained, the doctor-patient relationship may focus more on 
treatment efficacy than on side effects, which might be overlooked or not described or 
reported in the medical charts. Of note, an Italian study examining separate collection of 
chemotherapy-related side effect data by doctors and nurses found greater agreement 
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between patients and nurses than between patients and doctors for most of the items 
evaluated 8.  
 Our study suffers from limitations common to similar studies in this area, and a 
randomized study would be difficult to conduct for methodological reasons. Patients were 
not involved in the development of the Italian version of the questionnaire, and it is possible 
that a lack of validation of the comprehension of the statements describing toxicities could 
be responsible, at least in part, for the observed discrepancies. Doctors at each center were 
aware of the study but not formally involved. Therefore, they may have consciously or 
unconsciously focused on the ten side effects considered in this study, thus potentially 
biasing the discrepancy in side effect reporting. This might have accounted for the lower 
discrepancy that we observed in centers that enrolled a low number of patients. Indeed, in 
a prospective study of an 11-item version of the CTCAE distributed to 435 cancer patients 
and their doctors, there was good agreement between doctors and patients for most side 
effects 5. However, for those side effects with a subjective component (e.g., dyspnea, 
fatigue), agreement tended to be lower despite the involvement of both patients and doctors.  
 The strengths of this study are that it is large, prospective, and conducted in a 
homogeneous population of non-metastatic breast cancer patients with exclusion of 
potential confounders related to baseline cancer symptoms. Most patients were healthy and 
received anthracycline-based regimens with only minor dose variations at the different 
participating institutions. Finally, patients received chemotherapy in routine clinical practice 
and not in a prospective therapeutic trial mandating standardized reporting of side effects 
by the treating oncologist.  
We believe that the approach that we tested in this manuscript offers a number of 
potential advantages in cancer patients undergoing chemotherapy, in particular those 
treated in the clinical practice. For example, doctor-patient interaction would benefit from 
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using a common reference system for reporting and grading toxicity. With the diffusion of 
electronic medical records and the possibility that patients fill in electronic questionnaires, 
CTCAE-compliant patient reports could be immediately available to treating doctors. 
Patients can be reassured that doctors adequately weigh their personal experience with side 
effects, which my result with better coping and quality of like during treatment. Reconciliation 
of discrepancies in patient and doctor reports during the visit would improve decision making 
regarding chemotherapy dosing (i.e. dose delay or dose reduction). This may acquire a 
particular importance in those high-volume centers, where a constrained doctor-patient 
relationship may be the cause of underreporting of side effects by doctors.  
Conclusions 
In summary, this prospective study confirms that breast cancer patients receiving 
conventional therapy can provide CTCAE-compliant reporting and grading of common side 
effects related to adjuvant chemotherapy. Similar to other studies, we found that doctors 
tend to underreport or underestimate side effects. However, although we provide some 
explanation for this phenomenon, there is currently little direct evidence to explain doctor-
related factors, and further studies are warranted 18.   
 Addressing these open questions is becoming increasingly relevant and, in 
recognition of the importance of considering direct patient involvement in side effect 
collection and grading, the National Cancer Institute is financing, supporting, and 
disseminating a PRO version of the CTCAE system (PRO-CTCAE) 15 based on 78 toxicity 
items mapped to the CTCAE. For each toxicity, PRO-CTCAE contains up to three patient 
questions that define the grade of severity. These questions were developed and validated 
using a methodologically robust process based on cognitive interviewing techniques 21 The 
English version of PRO-CTCAE is currently being translated into different languages, 
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including Italian. Our data support the adoption of PRO and highlight the potential of this 
approach in routine clinical practice. 
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Figure Legend 
Figure 1. Discrepancy in toxicity grading between patients and doctors (first questionnaire) 
 
Figure 2. Correlation between discrepancy in patient and doctors reporting  of toxicity grade of each 
side effect and number of patients enrolled at each center (first questionnaire). Each circle represents 
a participating Institution. The size of each circle represents the number of patients enrolled in the 
study. 
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Table 1. Summary of paired patient questionnaire results 
Item* First  
Questionnaire 
% (N) 
Second  
Questionnaire 
% (N)  
Differences between 
Second and First 
Questionnaire  
(95%CI) 
P values** 
Nausea (550)     
 Incidence  69 (379) 73 (402) 4 (0; 8) 0.05 
 Mean Grade 1.16 1.13 -0.03 (-0.11; 0.05) 0.60 
     
Vomiting (566)     
 Incidence  24 (136) 20 (114) -4 (-8; -1) 0.06 
 Mean Grade 0.34 0.26 -0.08 (-0.13; -0.02) 0.01 
     
Constipation (554)     
 Incidence 52 (298) 49 (271) -3 (-8; 1) 0.21 
 Mean Grade 0.68 0.65 -0.03 (-0.10;0.03) 0.43 
     
Anorexia (567)     
 Incidence 54 (306) 53 (298) -1 (-6; 3) 0.56 
 Mean Grade 0.71 0.68 -0.03 (-0.09;0.04) 0.57 
     
Dysgeusia (537)     
 Incidence 51 (276) 58 (314) 7 (2; 12) <0.01 
 Mean Grade 0.63 0.73 0.1 (0.04; 0.16) <0.01 
     
Diarrhea (550)     
 Incidence 16 (87) 12 (65) -4 (-7; -1) 0.02 
 Mean Grade 0.19 0.14 -0.05 (-0.1; -0.01) 0.03 
     
Fatigue (544)     
 Incidence 77 (418) 78 (425) -1 (-5; 3) 0.58 
 Mean Grade 1.16 1.15 0.01 (-0.07; 0.08) 0.73 
     
Pain (556)     
 Incidence 36 (203) 32 (180) -4 (-8; 1) 0.08 
 Mean Grade 0.65 0.54 -0.11 (-0.20; -0.03) <0.01 
     
Paresthesia (558)     
 Incidence 23 (130) 21 (119) -2 (-6; 2) 0.35 
 Mean Grade 0.28 0.29 0.01 (-0.05; 0.06) 0.86 
     
Dyspnea (552)     
 Incidence 25 (138) 29 (162) 4 (1; 8) 0.03 
 Mean Grade 0.40 0.47 0.07 (0.001; 0.14) 0.04 
 
Abbreviations: N, number; CI, confidence intervals 
*Number in parentheses indicate evaluable pairs of questionnaires for each single item.  
**P values for Incidence and Mean Grade were obtained by the McNemar Test with continuity correction 
and the Wilcoxon signed rank test, respectively. 95%CIs were computed using bootstrap resampling. 
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Table 2. Summary of paired patient and doctor questionnaires after cycle 1 
Item* Patient 
Questionnaire 
% (N) 
Doctor 
Questionnaire 
% (N) 
Differences between 
Patient and Doctor 
Questionnaires  
(95%CI) 
P values** 
Nausea (539)     
 Incidence 67 (360) 40 (216) 27(22;31) <0.01 
 Mean Grade 1.10 0.59 0.51 (0.43;0.59) <0.01 
     
Vomiting (572)     
 Incidence  22 (128) 11 (62) 11(9; 14) <0.01 
 Mean Grade 0.31 0.16 0.15 (0.11; 020) <0.01 
     
Constipation (546)     
 Incidence 49 (268) 12 (65)  37(33; 41) <0.01 
 Mean Grade 0.64 0.15 0.49 (0.42; 0.54) <0.01 
     
Anorexia (563)     
 Incidence 53 (297) 7 (41) 46 (41; 50) <0.01 
 Mean Grade 0.69 0.09 0.60 (0.53; 0.66) <0.01 
     
Dysgeusia (556)     
 Incidence 50 (277) 8 (46) 42 (37; 46) <0.01 
 Mean Grade 0.61 0.10 0.51 (0.45; 0.57) <0.01 
     
Diarrhea (567)     
 Incidence 14 (81) 4 (25) 10 (7; 13) <0.01 
 Mean Grade 0.17 0.06 0.11 (0.07; 0.14) <0.01 
     
Fatigue (532)     
 Incidence 75 (400) 25 (132) 50 (46; 55) <0.01 
 Mean Grade 1.11 0.35 0.76 (0.71; 0.79) <0.01 
     
Pain (517)     
 Incidence 32 (165) 10 (52) 22 (18; 26) <0.01 
 Mean Grade 0.56 0.15 0.41 (0.33; 0.50) <0.01 
     
Paresthesia (582)     
 Incidence 23 (132) 3 (17) 20 (16; 23) <0.01 
 Mean Grade 0.27 0.04 0.23 (0.19; 0.26) <0.01 
     
Dyspnea (574)     
 Incidence 25 (142) 2 (13) 23 (19; 26) <0.01 
 Mean Grade 0.39 0.04 0.35 (0.29; 0.41) <0.01 
 
Abbreviations: N, number; CI, confidence intervals 
*Number in parentheses indicate evaluable pairs of questionnaires for each single item.  
**P values for Incidence and Mean Grade were obtained by the McNemar Test with continuity correction 
and the Wilcoxon signed rank test, respectively. 95% CIs were computed using bootstrap resampling. 
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Table 3. Concordance between patient and doctor questionnaires (missing data 
excluded) for side effect incidence (yes vs not) 
Toxicity 
N 
Patient  yes 
Doctor yes 
% (N) 
Patient yes 
Doctor No 
% (N) 
Patient no 
Doctor yes 
% (N) 
Patient No 
Doctor No 
% (N) 
 
statistic 
95% C.I. 
Nausea  539 35 (191)  31 (169) 5 (25) 29 (154) 0.32 0.26-0.39 
Vomiting 572 10 (58) 13 (70) 1 (4) 78 (440) 0.54 0.46-0.63 
Constipation 546 10 (57) 39 (211) 1 (8) 49 (270) 0.20 0.13-0.24 
Anorexia 563 6 (36)  46 (261) 1 (5) 46 (261) 0.10 0.06-0.14 
Dysgeusia 556 8 (43)  42 (234) <1 (1) 50 (276) 0.14 0.10-0.19 
Diarrhea 567 4 (21)  11 (60) 1 (4) 85 (482) 0.35 0.24-0.47 
Fatigue 532 23 (124) 52 (276) 2 (8) 23 (124) 0.15 0.11-0.19 
Pain 517 6 (31) 26 (134) 4 (21) 64 (331) 0.16 0.08-0.23 
Paresthesia 582 2 (13)  20 (119) 1 (4) 77 (446) 0.13 0.06-0.20 
Dyspnea 574 2 (11) 23 (131) <12 75 (430) 0.11 0.05-0.17 
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Figure 1. Correlation for the First Questionnaire Between Discrepancy in Patient and Physician Reporting ofAdverse 
Effect Grade and Number of Patients Enrolled at Each Center 
